buy

Regeneron Pharmaceuticals Inc. buy BMO Capital Markets

Regeneron Pharmaceuticals Inc.

Start price

€625.20

/ 50%

Target price

04.12.26

Performance (%)

Price

Summary

This prediction is currently active. The prediction currently has a performance of . This prediction currently runs until 04.12.26. The prediction end date can be changed by BMO_Capital_Markets at any time. BMO_Capital_Markets has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Feedback

Performance without dividends (%)

Name	1w	1m
Regeneron Pharmaceuticals Inc.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by BMO_Capital_Markets for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren

Prediction Buy

Perf. (%)

Target price 728.790

Change

Ends at

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at BMO Capital Markets from $725.00 to $850.00. They now have an "outperform" rating on the stock.

Ratings data for REGN provided by MarketBeat

BMO Capital Markets